Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares Earnings Dividend

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares’s revenue jumped 55.51% since last year same period to $214.27Mn in the Q1 2026. On a quarterly growth basis, Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares has generated 6.01% jump in its revenue since last 3-months.

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares’s net profit jumped 164.57% since last year same period to $22.59Mn in the Q1 2026. On a quarterly growth basis, Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares has generated 59.11% jump in its net profits since last 3-months.

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares’s net profit margin jumped 70.14% since last year same period to 10.54% in the Q1 2026. On a quarterly growth basis, Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares has generated 50.1% jump in its net profit margins since last 3-months.

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares’s price-to-earnings ratio after this Q1 2026 earnings stands at 57.52.

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares’s earning per share (EPS) estimates for the current quarter stand at 0.3 - a -7.41% fall from last quarter’s estimates.

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares’s earning per share (EPS) estimates for the current year stand at 0.3.

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares’s earning per share (EPS) jumped 145.45% since last year same period to 0.27 in the Q1 2026. This indicates that the Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares has generated 145.45% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares’s return on assets (ROA) stands at 0.08.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares’s return on equity (ROE) stands at 0.14.